CN100384411C - Oral carbidopa/levodopa disintegrant tablet - Google Patents

Oral carbidopa/levodopa disintegrant tablet Download PDF

Info

Publication number
CN100384411C
CN100384411C CNB2006100650518A CN200610065051A CN100384411C CN 100384411 C CN100384411 C CN 100384411C CN B2006100650518 A CNB2006100650518 A CN B2006100650518A CN 200610065051 A CN200610065051 A CN 200610065051A CN 100384411 C CN100384411 C CN 100384411C
Authority
CN
China
Prior art keywords
parts
oral cavity
microcrystalline cellulose
cavity disintegration
disintegration tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2006100650518A
Other languages
Chinese (zh)
Other versions
CN1857245A (en
Inventor
王锦刚
蒋海松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Kexin Bicheng Medicine Technology Development Co Ltd
Original Assignee
Beijing Kexin Bicheng Medicine Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Kexin Bicheng Medicine Technology Development Co Ltd filed Critical Beijing Kexin Bicheng Medicine Technology Development Co Ltd
Priority to CNB2006100650518A priority Critical patent/CN100384411C/en
Publication of CN1857245A publication Critical patent/CN1857245A/en
Application granted granted Critical
Publication of CN100384411C publication Critical patent/CN100384411C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses an oral carbidopa/levodopa disintegration tablet which uses carbidopa and levodopa as the main medicines. The oral carbidopa/levodopa disintegration tablet also comprises a disintegrating agent and a diluting agent. The oral carbidopa/levodopa disintegration tablet is characterized in that the disintegrating agent is low-substituted hydroxypropyl cellulose, and the diluting agent is prepared from microcrystalline cellulose and mannitol. The present invention also provides a production method of the oral carbidopa/levodopa disintegration tablet. The production method has the advantage of simple and stable technology, and is particularly suitable for industrial production.

Description

Oral carbidopa/levodopa disintegrant tablet
Technical field
The present invention relates to a kind of oral carbidopa/levodopa disintegrant tablet and its production method, specifically, relate to a kind of with the oral cavity disintegration tablet and the production method thereof of Carbidopa as principal agent.Described oral carbidopa/levodopa disintegrant tablet can be used for treating parkinson or parkinsonism etc.
Background technology
The maincenter that enters after levodopa is oral changes into dopamine and plays a role, carbidopa is a periphery deacidification enzyme inhibitor, be difficult for entering maincenter, only suppress the periphery levodopa and change into dopamine, make that levodopa content increases in the circulation, thereby the amount that enters the levodopa of maincenter increases also, levodopa is converted into dopamine and brings into play pharmacological action through the dopamine decarboxylation in brain, improve the Parkinsonism symptom, be used for the treatment of parkinson or parkinsonism etc.
Disclose a kind of treatment parkinson medicament among the CN1358090A, its main component is levodopa, carbidopa and entacapone.But disclosed a kind of dispersive composition of L-DOPA ethyl ester among the CN1329487A, wherein comprised carbidopa, disintegrating agent, filler and lubricant.
Summary of the invention
Oral cavity disintegration tablet is the ideal that is difficult to swallow the parkinson of the moderate of full wafer medicine or severe symptom or the parkinsonism patient dosage form of taking medicine.
The present invention selects by prescription screening and adjuvant on the basis of existing technology, is surprised to find that the oral cavity disintegration tablet of Carbidopa by selecting for use suitable disintegrating agent and diluent to be prepared from has excellent tablet effect.Oral carbidopa/levodopa disintegrant tablet of the present invention, preparation are formed and are different from the existing medicament that disperses.
The invention provides a kind of oral cavity disintegration tablet, with Carbidopa as principal agent, wherein the weight ratio of Carbidopa is 1: (4~10), comprise disintegrating agent and diluent, it is characterized in that described disintegrating agent is low-substituted hydroxypropyl cellulose (L-HPC), described diluent is microcrystalline Cellulose (CMCC) and mannitol.
Wherein said microcrystalline Cellulose can be microcrystalline Cellulose pH102, microcrystalline Cellulose pH301 or microcrystalline Cellulose KG802, also can be microcrystalline Cellulose-90 (CMCC 90) or microcrystalline Cellulose-50 (CMCC 50).Wherein, preferably microcrystalline cellulose is microcrystalline Cellulose pH102, microcrystalline Cellulose pH301 or microcrystalline Cellulose KG802.
Wherein, the consumption of microcrystalline Cellulose and mannitol, by weight calculating, can be (1~2): (1~1.5) is preferably 2: 1.
Above-mentioned described oral cavity disintegration tablet also comprises fluidizer, lubricant or correctives.Wherein, described fluidizer for example is one or more in micropowder silica gel, Pulvis Talci, Cab-O-sil, Arosil, the hydrated sodium aluminosilicate etc.; Described lubricant for example is one or more in magnesium stearate, calcium stearate, zinc stearate, glyceryl monostearate, Polyethylene Glycol, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene monostearate, single Laurel sucrose acid ester, sodium laurylsulfate, magnesium laurylsulfate, Stepanol MG and the Pulvis Talci etc.; Described correctives for example is one or more in aspartame, flavoring banana essence, flavoring pineapple essence, vanillin, fragrant citrus essence, flavoring orange essence, Herba Menthae essence, ginseng essence, strawberry essence, citric acid, the citric acid etc.
Preferred oral cavity disintegration tablet of the present invention is: calculate by weight, 10~25 parts of carbidopas, 100 parts of levodopa, 150~200 parts of microcrystalline Cellulose, 100~150 parts in mannitol, 20~30 parts of low-substituted hydroxypropyl celluloses, 2~8 parts of micropowder silica gels, 2~6 parts of magnesium stearate, 0.5~4 part of aspartame, 0.5~2 part in fragrant citrus essence, 0.5~2 part in Herba Menthae essence.
As one of specific embodiments of the present invention, described oral cavity disintegration tablet is: calculate 10 parts of carbidopas by weight, 100 parts of levodopa, 150 parts of microcrystalline Cellulose pH102,50 parts of microcrystalline Cellulose pH301,100 parts in mannitol, 25 parts of low-substituted hydroxypropyl celluloses, 5 parts of micropowder silica gels, 3.6 parts of magnesium stearate, 2 parts of aspartames, 1 part in fragrant citrus essence, 1 part in Herba Menthae essence.
As one of specific embodiments of the present invention, described oral cavity disintegration tablet is: calculate 10 parts of carbidopas, 100 parts of levodopa by weight, 200 parts of microcrystalline Cellulose pH102,100 parts in mannitol, 25 parts of low-substituted hydroxypropyl celluloses, 5 parts of micropowder silica gels, 3.6 parts of magnesium stearate, 2 parts of aspartames, 1 part in fragrant citrus essence, 1 part in Herba Menthae essence.
Oral cavity disintegration tablet of the present invention has suitable hardness, and preferred hardness is between 20~40N (newton).
Above-mentioned described oral cavity disintegration tablet can be used for preparing the medicine of diseases such as treatment parkinson or parkinsonism.
Can adopt direct compression process to prepare oral cavity disintegration tablet of the present invention.The production method of oral cavity disintegration tablet of the present invention, it comprises following steps: crude drug and adjuvant were with proper method (dilution method etc. for example progressively increases) mix homogeneously during (1) will write out a prescription; (2) adjust compression force to suitable sheet hardness (for example 20~40N), carry out tabletting.After the process quality examination was qualified, packing promptly got oral cavity disintegration tablet.
The inventor is with reference to the correlational study of existing oral cavity disintegration tablet, and in conjunction with the own characteristic of Carbidopa, by adjuvant is screened, be surprised to find that, with low-substituted hydroxypropyl cellulose (L-HPC) as disintegrating agent, particularly microcrystalline Cellulose pH102, microcrystalline Cellulose pH301 or microcrystalline Cellulose KG802 and mannitol are as diluent with microcrystalline Cellulose, and the oral cavity disintegration tablet that makes has excellent beneficial effect.Orally disintegrating tablet production method of the present invention, technology is simple, stable, is suitable for commercial production especially.
Description of drawings
The carbidopa stripping curve figure of accompanying drawing 1: embodiment 1 oral cavity disintegration tablet
The levodopa stripping curve figure of accompanying drawing 2: embodiment 1 oral cavity disintegration tablet
The specific embodiment
Come further the present invention to be made an explanation below by embodiment, but be not appreciated that it is that the scope of the invention is construed as limiting.
Embodiment 1: preparation embodiment
Carbidopa 10 grams, levodopa 100 grams, microcrystalline Cellulose pH102 200 grams, mannitol 100 grams, low-substituted hydroxypropyl cellulose 25 grams, micropowder silica gel 5 grams, magnesium stearate 3.6 grams, aspartame 2 grams, fragrant citrus essence 1 gram, Herba Menthae essence 1 gram.Crude drug and adjuvant were waited 80 mesh sieves, by the dilution method mixing that progressively increases, survey content of powder, regulating the tablet loading amount makes sheet heavily be heavy ± 3% weight of theoretical sheet, regulate the compression force tabletting, get tablet and survey hardness, regulate compression force and make tablet hardness in 20~40 newton, dash with the circular scrobicula of φ 12mm, be pressed into 1000.
Embodiment 2: preparation embodiment
Carbidopa 10 grams, levodopa 100 grams, microcrystalline Cellulose pH102 150 grams, microcrystalline Cellulose pH30150 gram, mannitol 100 grams, low-substituted hydroxypropyl cellulose 25 grams, micropowder silica gel 5 grams, magnesium stearate 3.6 grams, aspartame 2 grams, fragrant citrus essence 1 gram, Herba Menthae essence 1 gram.Make 1000 according to embodiment 1 described method.
Embodiment 3: preparation embodiment
Carbidopa 25 grams, levodopa 100 grams, microcrystalline Cellulose pH102 150 grams, microcrystalline Cellulose KG80250 gram, mannitol 100 grams, low-substituted hydroxypropyl cellulose 30 grams, micropowder silica gel 5 grams, magnesium stearate 3.6 grams, aspartame 2 grams, fragrant citrus essence 1 gram, Herba Menthae essence 1 gram.Make 1000 according to embodiment 1 described method.
Embodiment 4: contrast test
Embodiment 4a: with the low-substituted hydroxypropyl cellulose in the cross-linking sodium carboxymethyl cellulose 25 gram alternative embodiments 1, all the other all are same as embodiment 1.Make 1000 according to embodiment 1 described method.
Embodiment 4b: with the low-substituted hydroxypropyl cellulose in the polyvinylpolypyrrolidone 25 gram alternative embodiments 1, all the other all are same as embodiment 1.Make 1000 according to embodiment 1 described method.
Embodiment 4c: with the mannitol in the erithritol 100 gram alternative embodiments 1, all the other all are same as embodiment 1.Make 1000 according to embodiment 1 described method.
Key property to the oral cavity disintegration tablet of embodiment 1~4 is investigated.The results are shown in Table 1.
Wherein the disintegration time mensuration method is:
Method 1: small beaker method: get 1 5ml small beaker, add 2ml water, sheet is placed in one, the disintegration time of record tablet.
Method 2: instrument test method: for the lifting frequency that solves the disintegration tester that uses in the existing disintegration time mensuration method of Chinese Pharmacopoeia is fixed this shortcoming, with reference to some disintegration time mensuration methods of mentioning in the external oral cavity disintegration tablet patent, the present invention utilizes the hanging basket of 2000 editions two dissolution test systems of existing Chinese Pharmacopoeia and lift disintegration tester simultaneously.The former can regulate rotating speed.
Check: 37 degrees centigrade of waters bath with thermostatic control that the beaker that digestion instrument is equipped with at random places dissolution test system, inject 750 ml waters, hanging basket is installed on the dissolution test system by the basket axle, hanging basket is immersed in the water, make at the bottom of the hanging basket apart from the bottom of the beaker 5 centimetres; get this product, place the glass tubing of hanging basket.Start rotating shaft timing simultaneously, rotating speed is that per minute 50 or 80 changes, and tablet and powder is a disintegration time by the time of screen cloth all, the record disintegration time.The results are shown in Table 1
Table 1 oral carbidopa/levodopa disintegrant tablet prescription key property is investigated the result
Figure C20061006505100071
Measurement result shows, oral carbidopa/levodopa disintegrant tablet of the present invention is a disintegrating agent with low-substituted hydroxypropyl cellulose, and microcrystalline Cellulose and mannitol are as diluent, and the oral cavity disintegration tablet of making has excellent galenic pharmacy effect.
Embodiment 5: dissolution is investigated test
Algoscopy: get this product, according to dissolution method (two appendix XC first methods of Chinese Pharmacopoeia version in 2000), with 750ml 0.1N hydrochloric acid solvent, rotating speed is that per minute 50 changes, operation in accordance with the law, in the time of 30 minutes, it is an amount of to get solution, filters, get subsequent filtrate, carry out assay, calculate dissolution
Embodiment 1 is carried out dissolution investigate, stripping curve is drawn in sampling in the time of 2,5,10,20,30 minutes.Stripping curve is seen Fig. 1 and 2.
Oral cavity disintegration tablet of the present invention (getting embodiment 1 sample), according to the medicine stability test guideline, (investigate 10 under 45001x ± 5001x), high temperature (60 degrees centigrade), high humidity (relative humidity is 90% ± 5%) condition, investigate its stability at strong illumination respectively.Result of the test shows that product stability is good, and related substance and content all meet the requirements.
The present invention is described according to preferred embodiment.Should be understood that the description of front and embodiment are just to illustrating the present invention.Under prerequisite without departing from the spirit and scope of the present invention, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.

Claims (10)

1. oral cavity disintegration tablet, with Carbidopa as principal agent, wherein the weight ratio of Carbidopa is 1: (4~10), comprise disintegrating agent and diluent, it is characterized in that described disintegrating agent is a low-substituted hydroxypropyl cellulose, described diluent is microcrystalline Cellulose and mannitol, and the weight ratio of microcrystalline Cellulose and mannitol is 2: 1.
2. oral cavity disintegration tablet according to claim 1, wherein said microcrystalline Cellulose are selected microcrystalline Cellulose pH102, microcrystalline Cellulose pH301 or microcrystalline Cellulose KG802 for use.
3. according to claim 1 or 2 described oral cavity disintegration tablets, wherein also comprise fluidizer, lubricant or correctives.
4. oral cavity disintegration tablet according to claim 3 is characterized in that: calculate 10 parts of carbidopas by weight, 100 parts of levodopa, microcrystalline Cellulose pH102150 part, microcrystalline Cellulose pH30150 part, 100 parts in mannitol, 25 parts of low-substituted hydroxypropyl celluloses, 5 parts of micropowder silica gels, 3.6 parts of magnesium stearate, 2 parts of aspartames, 1 part in fragrant citrus essence, 1 part in Herba Menthae essence.
5. oral cavity disintegration tablet according to claim 3, it is characterized in that: calculate 10 parts of carbidopas, 100 parts of levodopa by weight, microcrystalline Cellulose pH102200 part, 100 parts in mannitol, 25 parts of low-substituted hydroxypropyl celluloses, 5 parts of micropowder silica gels, 3.6 parts of magnesium stearate, 2 parts of aspartames, 1 part in fragrant citrus essence, 1 part in Herba Menthae essence.
6. according to claim 1 or 2 described oral cavity disintegration tablets, the hardness that it is characterized in that sheet is between 20~40 newton.
7. oral cavity disintegration tablet according to claim 3, the hardness that it is characterized in that sheet is between 20~40 newton.
8. according to claim 4 or 5 described oral cavity disintegration tablets, the hardness that it is characterized in that sheet is between 20~40 newton.
9. each described oral cavity disintegration tablet of claim 1-8 is used for the treatment of purposes in parkinson or the parkinsonism medicine in preparation.
10. the production method of each described oral cavity disintegration tablet of claim 1-8 is characterized in that comprising following steps:
(1) will write out a prescription in crude drug and adjuvant proper method mix homogeneously;
(2) adjustment compression force to 20~40 newton's sheet hardness is carried out tabletting.
CNB2006100650518A 2006-03-17 2006-03-17 Oral carbidopa/levodopa disintegrant tablet Active CN100384411C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100650518A CN100384411C (en) 2006-03-17 2006-03-17 Oral carbidopa/levodopa disintegrant tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100650518A CN100384411C (en) 2006-03-17 2006-03-17 Oral carbidopa/levodopa disintegrant tablet

Publications (2)

Publication Number Publication Date
CN1857245A CN1857245A (en) 2006-11-08
CN100384411C true CN100384411C (en) 2008-04-30

Family

ID=37296233

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100650518A Active CN100384411C (en) 2006-03-17 2006-03-17 Oral carbidopa/levodopa disintegrant tablet

Country Status (1)

Country Link
CN (1) CN100384411C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101797244B (en) * 2010-04-01 2012-07-04 青岛科技大学 Levodopa/benserazide orally disintegrating tablet
CN104523671A (en) * 2014-11-20 2015-04-22 美吉斯制药(厦门)有限公司 Sinemet orally disintegrating tablet, and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168440C (en) * 1999-06-30 2004-09-29 欧里恩公司 Pharmaceutical formulation of levodopa/carbidopa/entacapone
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CN1739514A (en) * 2005-09-12 2006-03-01 重庆康刻尔制药有限公司 Oral loratadine disintegrating tablet and its prepn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168440C (en) * 1999-06-30 2004-09-29 欧里恩公司 Pharmaceutical formulation of levodopa/carbidopa/entacapone
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CN1739514A (en) * 2005-09-12 2006-03-01 重庆康刻尔制药有限公司 Oral loratadine disintegrating tablet and its prepn

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
口腔崩解片的研制进展. 柳松.中国药业,第14卷第11期. 2005
口腔崩解片的研制进展. 柳松.中国药业,第14卷第11期. 2005 *

Also Published As

Publication number Publication date
CN1857245A (en) 2006-11-08

Similar Documents

Publication Publication Date Title
Pawar et al. Development and evaluation of orodispersible tablets using a natural polysaccharide isolated from Cassia tora seeds
WO2010045788A1 (en) A orally disintegrating tablet of donepezil hydrochloride and the preparation method thereof
Gandhi et al. Comparative study on effect of natural and synthetic superdisintegrants in the formulation of orodispersible tablets
CN101411715B (en) Pharmaceutical composition containing acarbose
CN101461788B (en) Phloroglucine orally disintegrating tablet and preparation method thereof
CN101209249A (en) Spaston orally disintegrating tablets and preparation thereof
CN102631329A (en) Oral paroxetine disintegrating tablet and preparation process thereof
CN101336904B (en) Acarbose chewable tablets and preparation method thereof
CN100384411C (en) Oral carbidopa/levodopa disintegrant tablet
CN102440973B (en) Diphenhydramine citrate orally disintegrating tablet and preparation method thereof
CN104706605B (en) A kind of preparation method and resulting product of memantine oral solid tablet
CN101991559B (en) Stable Agomelatine capsule medicine composition
CN113384549A (en) Acetaminophen vitamin C effervescent tablet and preparation method thereof
CN101361720A (en) Nebivolol hydrochloric acid orally disintegrating tablet and preparation method thereof
CN105476971A (en) Medical composition for treating cold and preparation method of medical composition
CN105853382B (en) A kind of Li Gelieting oral disintegrating tablet and preparation method thereof
CN101401796A (en) Pramipexole orally disintegrating tablets and preparation method thereof
CN113274365B (en) Ramelteon quick-release slow-release double-release preparation and preparation method thereof
EP2726063A1 (en) Ibuprofen chewable tablet
CN101467985B (en) Bisoprolol fumarate dispersible tablet and preparation method thereof
CN1927301A (en) Tongmai Jiangzhi dispersant tablet and method for making same
CN106727371B (en) Donepezil hydrochloride pharmaceutical composition and preparation method thereof
JP2020066610A (en) Estradiol production promoting pharmaceutical composition and food composition
CN105434378B (en) Mei Suoshuli dispersible tablets and preparation method thereof
JP2007039337A (en) Health functional food tablet

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15

Patentee after: Beijing Kexin Bicheng Medicine Science & Technology Developing Co., Ltd.

Address before: 100080, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District

Patentee before: Beijing Kexin Bicheng Medicine Science & Technology Developing Co., Ltd.